C2N Diagnostics

11/17/2025

Publication Alert: The Journal of Personalized Medicine recently published “Implementation of an Alzheimer’s Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study.”

https://www.mdpi.com/2075-4426/15/10/469

Recent guidelines and workshop recommendations highlight the important role of Alzheimer’s disease (AD) blood tests in patient care. Real world implementation of these tests into clinical practice, however, has not been extensively evaluated. The objective of this study was to assess the implementation of the multi-analyte PrecivityAD2™ blood test (C2N Diagnostics) into the clinical workflow of memory care clinics.

The findings from this implementation study show that the PrecivityAD2 test was clinically useful, easy to incorporate into care, and associated with high health care professional (HCP) acceptance of the technology. As health systems pivot toward more effective diagnostic tools for facilitating AD diagnosis in clinical practice, the findings from this study provide valuable insights for the broader adoption of AD blood testing in personalized medicine and clinical practice settings.

Key Findings:
•Technology Assessment Model: Acceptance scores averaged 9.6 out of 10 (p < 0.0001, effect size 0.840); HCPs rated the test’s utility in “improving their diagnostic certainty,” “contribution to clinical decision-making,” and “ease of understanding test results” the highest among the attributes listed.
•Net Promoter Score (NPS): HCPs indicated excellent levels of trust and satisfaction for the test in their memory clinics with an NPS score of 75 (p < 0.0001) versus reference NPS score of 30, a benchmark value that is considered good in the healthcare setting. The extremely high NPS score from this study on the PrecivityAD2 test suggests that a significant majority of HCPs are likely to recommend the test to other HCPs.
•Coin Analysis/constant sum analysis: HCPs indicated that the test report’s APS2 result and the values of the two analyte ratios were of importance in their clinical decision-making, with 5.3 coins assigned to the APS2 result (53%) and 4.7 coins assigned to the analyte ratio values (47%).
•Open ended feedback from HCPs reinforced these observations for usefulness, ease of use and the test result reporting in clinical decision making.

Background/Objectives: A high-performing blood biomarker (BBM) test for Alzheimer’s disease (AD) represents an accurate, accessible, and scalable tool to aid healthcare professionals (HCPs) evaluating patients presenting with signs or symptoms of mild cognitive impairment (MCI) or dementia. Howeve...

11/14/2025

C2N is honored that the Human Proteome Organization (HUPO), the nonprofit international scientific organization that represents and promotes proteomics on a global stage, has named members of the scientific teams at C2N Diagnostics and the Bateman Lab and the Holtzman Lab at Washington University School of Medicine as recipients of the HUPO 2025 Scientific and Technology Award. Dr. Joel Braunstein accepted the award on behalf of C2N and Washington University.

HUPO says it selected the C2N and WashU Medicine teams because their “exceptional achievements have significantly advanced the field of proteomics. Each award recognizes excellence, innovation, and impactful contributions to the global scientific community.”

Congratulations to all the scientists recognized for this award in excellence!

11/12/2025

C2N Diagnostics is proud to participate in the Gerontological Society of America (GSA) 2025 Annual Scientific Meeting in Boston, MA, November 12 - 15. C2N will be sharing The Effect of Patient Age, S*x, Race, and Ethnicity on Decision-Making Around An Alzheimer's Disease Blood Test: QUIP II Study Results at Poster Session (7010) Alzheimer’s Disease and Related Dementias on Wednesday, November 12 from 6:00 - 7:15 PM in the Hynes Convention Center Room - Exhibit Hall C - Poster Board 53.

Please visit our C2N exhibit booth to talk with our team.

11/11/2025

Congratulations to Dr. Randall Bateman, the entire Bateman Lab team, and Washington University School of Medicine on the informative CBS Sunday Morning feature on the critical Alzheimer’s disease research taking place in St. Louis. Dr. Bateman, a C2N Scientific Co-Founder, continues his life-long work in Alzheimer’s on an early and accurate diagnosis for patients and towards the ultimate research breakthrough - the prevention of Alzheimer’s.

Our focus is simple: stop Alzheimer’s before it starts. This disease steals the moments that make us who we are and the memories we share. That’s why we believe in attacking Alzheimer’s from every angle — because every breakthrough means more time, more hope and more moments together for fam...

11/10/2025

Congratulations to C2N’s own roadrunner, Brianne Peters, who recently completed the Alzheimer’s Association’s Chicago Marathon. Brianne was part of the AlzStars team in Chicago that raised over $1.2M for the Alzheimer’s Association to fund Alzheimer’s research.

Way to go, Brianne! Thanks for all that you do to support ending Alzheimer’s disease.

11/03/2025

On Wednesday, November 5, Dr. Joel Braunstein, MD, CEO of C2N Diagnostics, will provide a keynote presentation on "A Moment in Medicine: Redefining Clinical Care in Alzheimer's Disease Through Precision Diagnostics” at the Rosalind Franklin University of Medicine
and Science in North Chicago, IL.
Registration information is included in the announcement below.

Our 4th annual Biomedical Innovation Day is coming up fast! Don't miss out on a fantastic networking and learning opportunity. Discover advances in brain health, with a keynote speech by Dr. Joel Braunstein, MD from C2N Diagnostics on "A Moment in Medicine: Redefining Clinical Care in Alzheimer's Disease Through Precision Diagnostics."

Register today and hear from an impressive lineup of RFU speakers and guest speakers from Rush Medical University, Healthcare Foundation of Northern Lake County, University of Illinois Chicago, Alzheimer's Association, UP Oncolytics, Inc, Vanqua Bio and Cures Within Reach. https://www.givecampus.com/schools/RosalindFranklinUniversity/events/rfu-s-4th-annual-biomedical-innovation-day

10/27/2025

Don't miss this exciting Cambridge Cognition webinar on Wednesday, October 29 featuring C2N Diagnostics CEO, Dr. Joel Braunstein speaking on "Integrating Blood Biomarker Tests and Digital Cognitive Assessments to Accelerate Brain Health Research." Registration is free of charge.

WEBINAR ALERT
Advances in research have identified hallmarks of Alzheimer’s disease through blood biomarker tests (BBM). Compared to traditional imaging methods, BBMs are more accessible, cost-effective, and is a very promising tool for advancing diagnosis among individuals with cognitive concerns.

The implementation of BBMs with digital cognitive assessments (DCA) in clinical research applications can bring several advantages, such as identifying people at risk of developing conditions such as Alzheimer’s disease as well as facilitating disease monitoring.

This expert-led webinar will discuss research challenges, and give you the opportunity to ask the experts in our live Q&A .

Learn how the strategic integration of BBMs and DCAs can improve detection, enhance precise monitoring, and potentially, more effective therapeutic intervention.

In this 60-minute webinar on Oct. 29, you will:
• Uncover the critical limitations of conventional assessment methods like CSF/PET and paper-and-pencil tests in modern neurological research.

• Learn how combining BBMs and DCAs can provide a multi-dimensional view of brain health.

• Identify concrete strategies to improve participant screening, enhance recruitment, and implement more sensitive monitoring of disease progression and treatment effects.

• Gain practical knowledge on implementation, from tool selection and data integration to navigating the challenges of standardization and validation.

• See how richer, integrated datasets that connect biological signals to clinical manifestations can lead to more compelling evidence for regulators.

Speakers:
Martina De Lillo, PhD, Clinical Scientist
Francesca Cormack, PhD, Chief Scientist
Joel B. Braunstein, MD, MBA, Co-Founder and CEO, C2N Diagnostics
Christoffer Hatlestad-Hall, PhD, Postdoctoral Researcher

238abbf4-70e9-4c4b-b336-7b09df1d6302@9965b91a-cdae-477c-8430-54e57a5778e6" rel="ugc" target="_blank">https://events.teams.microsoft.com/event/238abbf4-70e9-4c4b-b336-7b09df1d6302@9965b91a-cdae-477c-8430-54e57a5778e6

10/14/2025

On October 15th, The Atlantic and WashU Olin Business School will convene a free half day Summit in St. Louis to explore how medical breakthroughs – especially in complex fields like neurological disease – can move from discovery to real-world impact at scale. Dr. Joel Braunstein, CEO of C2N Diagnostics, will speak on a panel addressing “Beyond the Lab: Making Breakthroughs Reach People.”

Led by AtlanticLIVE contributor, Jeanne Meserve, Dr. Braunstein and other panelists will address how promising scientific discoveries emerge from academic labs and how science becomes system change and what it takes to navigate the complex path from research to commercialization, implementation, and broad adoption.

Register to attend virtually or in person - https://www.theatlantic.com/live/the-business-of-health/

10/06/2025

WEBINAR ALERT
Advances in research have identified hallmarks of Alzheimer’s disease through blood biomarker tests (BBM). Compared to traditional imaging methods, BBMs are more accessible, cost-effective, and is a very promising tool for advancing diagnosis among individuals with cognitive concerns.

The implementation of BBMs with digital cognitive assessments (DCA) in clinical research applications can bring several advantages, such as identifying people at risk of developing conditions such as Alzheimer’s disease as well as facilitating disease monitoring.

This expert-led webinar will discuss research challenges, and give you the opportunity to ask the experts in our live Q&A .

Learn how the strategic integration of BBMs and DCAs can improve detection, enhance precise monitoring, and potentially, more effective therapeutic intervention.

In this 60-minute webinar on Oct. 29, you will:
• Uncover the critical limitations of conventional assessment methods like CSF/PET and paper-and-pencil tests in modern neurological research.

• Learn how combining BBMs and DCAs can provide a multi-dimensional view of brain health.

• Identify concrete strategies to improve participant screening, enhance recruitment, and implement more sensitive monitoring of disease progression and treatment effects.

• Gain practical knowledge on implementation, from tool selection and data integration to navigating the challenges of standardization and validation.

• See how richer, integrated datasets that connect biological signals to clinical manifestations can lead to more compelling evidence for regulators.

Speakers:
Martina De Lillo, PhD, Clinical Scientist
Francesca Cormack, PhD, Chief Scientist
Joel B. Braunstein, MD, MBA, Co-Founder and CEO, C2N Diagnostics
Christoffer Hatlestad-Hall, PhD, Postdoctoral Researcher

238abbf4-70e9-4c4b-b336-7b09df1d6302@9965b91a-cdae-477c-8430-54e57a5778e6" rel="ugc" target="_blank">https://events.teams.microsoft.com/event/238abbf4-70e9-4c4b-b336-7b09df1d6302@9965b91a-cdae-477c-8430-54e57a5778e6

10/03/2025

St. Louis magazine in C2N’s hometown names CEO Dr. Joel Braunstein to its Business 500 List👏

It’s “a guide to some of the metro area’s most influential, impactful, and innovative leaders.”

Click here to read a recap of Dr. Braunstein and C2N’s accomplishments www.stlmag.com/business/st-louis-business-500-health-care/

10/01/2025

🚨C2N Submits U.S. FDA Regulatory Filing for Its Alzheimer’s Disease Blood Test

Company Seeks to Establish a First in the Field of Medicine with Pioneering Diagnostic Algorithm Test Using High Resolution Mass Spectrometry

C2N believes this is a first for the entire field of medicine: the first multi-analyte algorithmic blood test using high-resolution mass spectrometry (HRMS) submitted for FDA review, for use in the assessment of Alzheimer’s disease pathology. HRMS is a powerful technology that represents a significant advancement in the field of clinical laboratory diagnostics, enabling the detection of circulating proteins from blood with high analytical sensitivity and specificity.

https://c2n.com/news-releases/c2n-submits-us-fda-regulatory-filing-for-its-alzheimers-disease-blood-test

10/01/2025

C2N CEO Dr. Joel Braunstein will be speaking at the Splash Clinical Summit, which is designed to “spark collaboration, share insights, and tackle some of the toughest challenges in clinical trials today.”

Dr. Braunstein will be discussing the role and value of blood biomarkers in Alzheimer’s disease research.

Further information👉https://www.splashclinical.com/the-second-annual-splash-clinical-summit-in-raleigh/

Learn more about Dr. Braunstein👉 https://c2n.com/our-team

Full details about C2N’s role developing and commercializing novel diagnostics for Alzheimer’s disease and related forms of neurodegeneration to improve treatment decisions and patients’ lives 👉www.C2N.com